SINGAPORE
Citing Quintiles’ innovation, customer service and growth, Frost & Sullivan has named Quintiles as its Asia Pacific Contract Research Organization Company of the Year.
“Quintiles is the clear market leader in the Asia Pacific CRO landscape,” said Rhenu Bhuller, Partner, Healthcare, Frost & Sullivan. “Asia Pacific is a strong focus area for multinational CROs and we evaluated the top five on two key factors – ‘visionary innovation and performance’ and ‘customer impact’. Quintiles scored highly in all criteria, and particularly so in ‘pioneering best practices’ and ‘addressing biopharma’s unmet needs’.
“For example, Quintiles launched a dedicated medical devices unit in Asia Pacific in 2015 that leverages the expertise of Novella Clinical, a Quintiles company. It also introduced a custom-tailored set of solutions for Asia Pacific emerging biopharma. Both of these are fast-growing market sectors and ones in which government and industry are trying to build capabilities. Quintiles is well-positioned to support this growth.”
Frost & Sullivan, a leading business research and consulting firm, also cited Quintiles’ continued expansion of services in Asia Pacific, particularly in Greater China, Japan and South Korea; and its use of innovative technologies to improve efficiency and quality.
Quintiles President and Head of Asia Pacific Anand Tharmaratnam said: “This honor belongs to our 10,000 plus employees across Asia Pacific who work every day to improve our customers’ probability of success. I believe Asia is entering a new era – one marked by global leadership in biopharma R&D and by diffusion of Asian innovation to global markets.
“With 60 percent of the world’s population, there is tremendous need in Asia Pacific for medicines that will deliver better value and improve patient outcomes. We’re very proud to receive this honor in recognition of our efforts to help achieve that.”
Quintiles opened its first Asia Pacific office (Tokyo) in 1993 and this year is celebrating the 20th anniversary of Quintiles Singapore, its Asia Pacific regional headquarters. With a database of more than 17,000 investigator sites or hospitals across Asia Pacific, Quintiles has conducted more than 1,100 studies covering a wide range of therapeutic areas – including cardiovascular disease, oncology, neurology and infectious diseases – involving almost 250,000 patients since 2000.
Over the last 12 months Quintiles has won the Vaccine Industry Excellence Best CRO Award; received SCRIP Awards Best CRO honors; and been named to the InformationWeek Elite 100. Earlier this year Dr. Tharmaratnam was named “Best Life Science Asian Male Executive of the Year” at the BioPharma Asia Industry Awards.
About Quintiles
Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151015005053/en/
CONTACT
Quintiles
Jay Johnson, Media Relations
+65.9655.6635
jay.johnson@quintiles.com
or
Todd
Kasper, Investor Relations
+1-919-998-2590
InvestorRelations@quintiles.com
